Biolidics Ltd

Chart & performance

D1W1MN

P/E

—

P/S

3.93

EPS

—

Div yield, %

—

Shrs. gr., 5y

46.07%

Rev. gr., 5y

-10.72%

Revenues

+570.79%

Net income

-4m

L+15.38%

CFO

-360k

L-84.44%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.

URL

https://www.biolidics.com/

IPO date

Dec 19, 2018

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SGD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SGD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT